Clinical Trials | September 03, 2024
Tolebrutinib meets primary endpoint in HERCULES phase 3 study
Phase 3 study results will form the basis for future discussions with global regulatory authorities
Phase 3 study results will form the basis for future discussions with global regulatory authorities
MyClad is a global Phase III study evaluating the efficacy and safety of cladribine capsules for the treatment of generalized Myasthenia Gravis (gMG)
Finerenone is the first mineralocorticoid receptor (MR) antagonist to demonstrate definitive cardiovascular benefits in a Phase III study in patients with heart failure (HF) with a left ventricular ejection fraction (LVEF) of ?40%
H.coagulans is, unlike other general lactobacillus, characterized by spore formation, giving it resistance to acid and heat
Stressed was on the need to promote organ donation from the deceased persons to meet the huge need for organ donation in the country
TABRECTA is the brand of Novartis. Natco believes it is the first company to have filed a substantially-complete ANDA
The study highlighted substantial improvements in key clinical parameters among RA patients who underwent AWS intervention
Brimonidine Tartrate Ophthalmic Solution, 0.1% is an alpha adrenergic receptor agonist indicated for the reduction of elevated intraocular pressure
Ordspono is Regeneron’s first approved bispecific antibody and will provide an off-the-shelf option that can be administered in the out-patient setting, with hope for complete remission
The new bioeconomy policy rolled out by the Modi government is set to place India as a global leader in the years to come
Subscribe To Our Newsletter & Stay Updated
